Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the lupus therapeutics market size evolved in recent years?

The market size for lupus therapeutics has demonstrated robust growth in the past years. The market is expected to expand from $2.74 billion in 2024 to $2.99 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.9%. This growth in the historical phase has been driven by factors such as elevated incidence rates of lupus, greater investment in healthcare infrastructure, high levels of disposable income, a significant demand for effective treatments, and an increasing aging population.

What are the predictions for the lupus therapeutics market size in the coming years?

The market for lupus therapeutics is predicted to experience solid growth in the coming years, with the expectation to reach a value of $4.16 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.7%. This growth for the forecasted period can be credited to an increase in drug approvals and launches, the rise of emerging markets, enhancements in disease recognition and diagnosis, heightened awareness initiatives, and the availability of immunosuppressive products. Notable trends during the forecast period encompass chimeric antigen receptor T-cell (CAR-T) therapy, small molecule treatments for lupus, CAR-NK therapy for lupus, the simultaneous inhibition of human plasmacytoid dendritic cell activity in systemic lupus, erythematosus (SLE), and urine proteomics.

Get your lupus therapeutics market report here!

https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

What key factors are fueling the growth of the lupus therapeutics market?

The growth of the lupus therapeutics market is expected to be spurred by the escalating activities in research and development. This term refers to ordered investigations and experiments aimed at making strides in the field of knowledge, technology, or product advancement in diverse sectors. The surge in research and development activities can often be attributed to the push for innovation, technological advancements, tackling upcoming challenges, ameliorating healthcare results, and promoting economic growth via scientific inventions and technological innovations. Such activities contribute to the progression of lupus therapeutics by identifying new remedies, refining current treatments, and comprehending the rudimentary mechanisms of the disease. For example, a Congressional Research Service report published in March 2023 stated that the national institutes of health, a US-based federal legislative branch agency, received a funding of $49.183 billion for research and development activities in 2023, an augmentation from the $42.941 billion allocated in 2021. As a result, the upswing in research and development activities is fuelling the growth of the lupus therapeutics market.

How is the global lupus therapeutics market divided into key segments?

The lupus therapeutics market covered in this report is segmented –

1) By Disease Type: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus

2) By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Biologics, Antimalarial Drugs, Corticosteroids, Other Treatment Types

3) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Routes Of Administration

4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Systemic Lupus Erythematosus (SLE): Mild SLE, Moderate SLE, Severe SLE

2) By Cutaneous Lupus Erythematosus: Acute Cutaneous Lupus, Subacute Cutaneous Lupus, Chronic Cutaneous Lupus (Including Discoid Lupus)

3) By Drug-Induced Lupus Erythematosus: Medications Known To Cause Drug-Induced Lupus, Hydralazine, Procainamide, Isoniazid

4) By Neonatal Lupus: Heart-Related Neonatal Lupus, Skin-Related Neonatal Lupus

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16471&type=smp

Who are the key firms paving the way for growth in the lupus therapeutics market?

Major companies operating in the lupus therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited

What are the key trends shaping the future of the lupus therapeutics market?

Leading businesses in the lupus therapeutics market are concentrating their efforts on creating advanced blood tests that incorporate predictive artificial intelligence for improved diagnostic accuracy and more effective treatment results. Predictive artificial intelligence in blood tests refers to diagnostic devices that employ AI algorithms to evaluate biomarkers found in blood sample, enabling a more accurate forecast of disease progression or therapeutic responses. For example, AMPEL BioSolutions LLC, a precision medicine company based in the US, rolled out the LuGENE blood test in March 2024. This test utilizes predictive AI to anticipate lupus flare-ups and drug responses according to gene expression data. The objective of this test is to radically alter lupus management – an autoimmune disorder, by offering tailor-made treatment alternatives for patients. It detects the occurrence of any unusual gene expression in real-time that triggers inflammation and disrupts normal functioning of the immune system, which are elements that can be controlled by medication.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16471

What regions are contributing significantly to the growth of the lupus therapeutics market?

North America was the largest region in the lupus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lupus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cystic Fibrosis (CF) Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Peptide Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Liver Diseases Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: